Pierre-Olivier Gaudreau MD PhD

Exploring the intersection between art and medicine: Join us for Dr. Jean Désy’s seminar on Friday November 14, 2025! eventbrite.ca/e/scri-present… @QueensUHealth @queensuResearch @CDNCancerTrials @QueensGlobalOnc @KingstonHSC @ModernFuelARC @oncology_bg @AndrewWCraig @SojungBahng

Dr. Joseph Pater #CCTG's founding director recognized for a lifetime of work in cancer research with his appointment as an Officer of the Order of Canada - his clinical research has improved the lives of Canadians with cancer. #OrderOfCanada #GGHonours  ctg.queensu.ca/cctg_news/foun…

(3/3) As well as the CCTG IND trial poster for the IND.238 trial (Dr. Peter Ellis & Dr. Sara Taylor): Time: Jun/3/2023, 8:00 AM-11:00 AM CDT Hall A meetings.asco.org/abstracts-pres… @INDProgramCCTG @CDNCancerTrials #immunotherapy #rechallenge #immunerelatedadverseevent

(2/3) I also invite you to visit our CCTG IND trial posters at ASCO, including IND.240 (Dr. Helen MacKay): Time: Jun/5/2023, 1:15 PM CDT Hall A meetings.asco.org/abstracts-pres… @INDProgramCCTG @CDNCancerTrials #immunotherapy #ovariancancer

(1/3) Going to ASCO this week? Join us for Dr. Quincy Chu's oral presentation highlighting the phase 3 results of the IND.227 trial in mesothelioma: Time: Jun/3/2023, 3:00 PM-6:00 PM CDT Hall B1 meetings.asco.org/abstracts-pres… @INDProgramCCTG @CDNCancerTrials #mesothelioma

Pleased to announce our June seminar speaker! Dr. Caroline Lamarche @lamarchecaroli1 will be presenting via Zoom on June 5th at noon. Hosted by @DrPOGaudreau For Zoom details, please email qcri@queensu.ca

@CJTsaiMDPhD @rweichselbaum @RohanKatipally @SeanPitroda @JYangMDPhD @xrtGenomics @IyengarPuneeth Thanks for sharing, Jillian. Very interesting - and aligned with my prior pre-clinical training at MD Anderson (credits to my mentor Dr. Don L. Gibbons, internationally recognized for his work on tumor plasticity and EMT in the context of thoracic malignancies).

Another great contribution to the scientific community providing genotypic insights to better understand the phenotypic characteristics. @rweichselbaum @RohanKatipally @SeanPitroda @JYangMDPhD @xrtGenomics @IyengarPuneeth @DrPOGaudreau

(1/3) Excited to share our work on genomic and transcriptomic predictors of response to PD-(L)1 inhibitors in NSCLC @NatureGenet; nearly 400 pts and growing, forming the SU2C/Mark Foundation cohort nature.com/articles/s4158…

Libérer le potentiel des femmes = libérer le potentiel de l’humanité ! ✨ En cette #JournéeDesFemmes, réclamons un monde digital inclusif. Le changement technologique et l’éducation à l’ère du numérique doivent nous aider à réaliser l'#ÉgalitéDesGenres. on.unesco.org/2EGAx9l

@CDNCancerTrials’s IND.227 phase 2 results comparing front-line IO vs CT vs IO + CT in advanced pleural mesothelioma are now available @JTOonline. Many thanks to the patients and their families, as well as to our team and all participating centres. jto.org/article/S1556-…

Happy #WomenInScience Day! Let us get rid of stereotypes, challenge gender bias and beat discrimination that hold women & girls back in science, technology, engineering and maths! on.unesco.org/WomenInScience

#CCTG is looking for a Patient Representative Volunteer to support the Lung Disease Site Committee & represent the perspective of patients & their families, & the public at large, in the development & delivery of clinical trials. #SolvingCancerTogether ctg.queensu.ca/bulletin/cctg-…

Dr. @DrJNaidoo discusses resistance to immunotherapy- important to have consistent terminology. Highlights importance of the gut microbiota and emerging circulating markers of resistance. #ILCDebates2023

Check out the @jitcancer Special Series on Liquid Biopsies! sitcancer.org/research/jitc-… jitc.bmj.com/content/11/1/e… jitc.bmj.com/content/11/1/e… jitc.bmj.com/content/10/12/… jitc.bmj.com/content/11/1/e… jitc.bmj.com/content/11/1/e… @md_stewart @CancerResrch @sitcancer @hopkinskimmel

Very promising work from our colleagues at McGill, using AI to predict early-stage NSCLC recurrence following surgery. Congratulations to the whole team! @sori_mark @loganwalsh @DanielaQuail @DoctorJspicer @PJoubertPatho @Miranda_WYu nature.com/articles/s4158…

@loganawalsh @Nature Very happy to see these papers published from such a great team. Congratulations!

Deeply saddened by news of Jill Hamer-Wilson’s passing. As a Patient Partner, Jill devoted her time and experience to clinical trial advocacy and transforming patient engagement in research. This week’s 3CTN Annual Stakeholder Meeting will be dedicated to her memory and legacy.

Review: iRECIST and atypical patterns of response to immuno-oncology drugs bit.ly/3ox42lf #JITC @DrPOGaudreau 3/4